# Wall Street Zen

Type: Company

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/wall-street-zen-company
Canonical HTML page: https://getfinancebrief.com/entity/wall-street-zen-company

## Timeline

- **2026-07-22**: Quarterly earnings released — SMBC reports EPS of $1.83 vs. $1.52 estimate, revenue of $51.77M.
- **2026-06-26**: Piper Sandler adjusts PT — Piper Sandler reiterates Neutral, boosts target from $71 to $79.
- **2026-06-11**: Three directors execute insider purchases — Philip Fracassa buys 5,000 MBC shares, Paul Koonce buys 500 SR shares, and Frederick Disanto buys 1,000 EML shares, all in open-market transactions.
- **2026-06-05**: Insider sale by EVP Windes — EVP Richard Windes sells 2,000 shares at average $69.70, totaling $139,400.
- **2026-06-04**: Weiss Ratings reiterates Buy — Weiss Ratings issues a 'buy (b)' rating on SMBC.
- **2026-05-12**: Eastern reports Q1 2026 earnings — EML delivers $0.11 EPS, missing the $0.50 estimate by $0.39; revenue of $59.68M trails the $67.74M consensus.
- **2026-05-06**: Spire reports Q2 2026 earnings — SR earns $3.76 per share, topping analyst expectations of $3.72 by $0.04; revenue of $1.02B misses consensus by $50M.
- **2026-05-05**: MasterBrand reports Q1 2026 earnings — MBC posts EPS of $0.06, beating consensus estimate of -$0.04 by $0.10; revenue of $618M beats estimates but declines 6.4% YoY.
- **2026-04-24**: Stephens bullish call — Stephens reiterates Overweight rating, lifts PT to $76 from $72.
- **2026-04-13**: RBC downgrades Eastern to Hold — Royal Bank of Canada cuts EML from Moderate Buy to Hold, likely after earnings miss.
- **2026-04-09**: KBW target price increase — Keefe, Bruyette & Woods raises price target from $64 to $65, maintaining Market Perform rating.
- **2026-03-24**: Sentiment Review — Major analysts maintain existing price targets and ratings despite the earnings beat.
- **2026-03-18**: Wall Street Zen Downgrade — Official rating cut to Hold for both TEAM and ON tickers.
- **2026-03-17**: Market Warnings — Analysts warn of a 'chaos tsunami' in the workforce due to rapid AI integration at tech firms.
- **2026-03-16**: Analyst Upgrade — Wall Street Zen upgrades CDXS rating following financial results.

## Recent coverage (17 stories)

### SMBC Beats EPS by $0.31, Stock Down 1.4% Amid Insider Selling
2026-07-23 00:54:41 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Southern Missouri Bancorp delivered a strong quarter with earnings of $1.83 per share, beating estimates by $0.31 on revenue of $51.77 million. However, the stock fell 1.4% to $75.41 as analysts remain divided and insider selling raises questions.
Full story: https://getfinancebrief.com/story/smbc-earnings-beat-stock-down-insider-sell

### Pentair Stock Tumbles as Q2 Guidance of $1.12 EPS Misses Consensus by 24%
2026-07-15 13:18:57 · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Pentair’s revised Q2 2026 guidance stunned investors, with EPS of $1.12 against a $1.48 estimate and revenue of $930M, well below the $1.1B consensus. The stock slid to $75.74 on heavy volume, its 200-day MA, and the new full-year EPS range of $4.60-4.80 implies a 10-14% miss, triggering a fresh round of analyst target cuts.
Full story: https://getfinancebrief.com/story/pentair-earnings-guidance-miss-stock-drop

### Aehr Test Systems Beats Q4 EPS by $0.06, Stock Jumps 5.9% — What’s Next?
2026-07-15 08:35:12 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Aehr Test Systems reported Q4 earnings of $0.05 per share, beating the consensus estimate of -$0.01 by $0.06. Despite negative net margins of -25.23% and insider selling, shares surged 5.9% to $72.01, with analysts mixed — two buys, one hold, one sell, and a Hold consensus with a $68 target.
Full story: https://getfinancebrief.com/story/aehr-earnings-beat-006-stock-surges

### Insiders Pour $106K Into EML, SR, MBC as Directors Boost Stakes by Up to 12.49%
2026-06-14 11:22:29 · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Three corporate directors executed open-market purchases totaling $106,030 on June 11, signaling potential undervaluation at Eastern, Spire, and MasterBrand. The buys ranged from a 0.99% stake boost at Eastern to a 12.49% jump at MasterBrand, despite mixed earnings and sell-side downgrades.
Full story: https://getfinancebrief.com/story/insider-buying-spree-2026-eastern-spire-masterbrand

### Codexis Holds Steady as ECO Synthesis Gains Traction Post-Q4 Earnings Beat
2026-03-24 23:00:38 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Codexis reported a significant Q4 2025 earnings beat, driven by its ECO Synthesis platform and expanding CDMO partnerships. Despite a raised 2026 revenue outlook and a surprise GAAP profit, analyst sentiment remains largely unchanged as the market awaits further commercial validation of its RNA manufacturing technology.
Full story: https://getfinancebrief.com/story/codexis-cdxs-earnings-analyst-sentiment-analysis

### Wall Street Zen Downgrades Atlassian and ON Semi Amid AI and Sector Shifts
2026-03-18 06:54:35 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wall Street Zen has lowered its ratings for Atlassian and ON Semiconductor to 'Hold,' reflecting a cooling sentiment toward high-growth tech and semiconductor leaders. The move comes as Atlassian navigates AI-driven restructuring and ON Semiconductor faces a maturing cycle in the automotive chip market.
Full story: https://getfinancebrief.com/story/atlassian-on-semiconductor-downgrade-wall-street-zen

### Wall Street Zen Downgrades SAB Biotherapeutics and SURO Capital to Sell
2026-03-17 06:53:16 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wall Street Zen has issued 'Sell' ratings for both SAB Biotherapeutics and SURO Capital, signaling a shift in sentiment for high-risk biotech and venture-backed assets. These downgrades reflect growing analyst caution regarding clinical-stage development timelines and private equity valuation gaps in the 2026 market environment.
Full story: https://getfinancebrief.com/story/sab-biotherapeutics-suro-capital-downgrade-wall-street-zen

### Alignment Healthcare Insider Sales Follow $257M Secondary Offering
2026-03-14 03:12:21 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Alignment Healthcare's President and another insider divested over 33,000 shares in mid-March, following a massive secondary offering and a rating downgrade. The sales come as the Medicare Advantage provider reports narrowing losses but faces a shift in analyst sentiment from 'Buy' to 'Hold.'
Full story: https://getfinancebrief.com/story/alignment-healthcare-insider-selling-secondary-offering

### Wall Street Zen Downgrades Weyco Group and Frontdoor to Hold as Outlook Cools
2026-03-11 06:27:01 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Investment research platform Wall Street Zen has lowered its ratings for footwear distributor Weyco Group and home services provider Frontdoor to 'Hold.' The shift reflects a more cautious outlook on consumer discretionary spending and the housing-adjacent service sector as both companies face evolving market conditions.
Full story: https://getfinancebrief.com/story/weyco-frontdoor-downgrade-wall-street-zen

### Wall Street Zen Upgrades Lakeland Financial and ADTRAN Amid Mid-Cap Recovery
2026-03-11 06:23:21 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Investment research platform Wall Street Zen has issued dual upgrades for regional lender Lakeland Financial and networking firm ADTRAN. The ratings shift follows a significant earnings beat by ADTRAN and a stabilizing outlook for Indiana-based Lakeland Financial.
Full story: https://getfinancebrief.com/story/wall-street-zen-upgrades-lkfn-adtn-analysis

### Wall Street Zen Downgrades Alignment Healthcare and Freshworks to Hold
2026-03-10 08:16:40 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wall Street Zen has lowered its investment ratings for Alignment Healthcare and Freshworks from Buy to Hold, signaling a shift to a neutral outlook. The downgrades reflect a cautious stance on the Medicare Advantage sector and the competitive SaaS landscape as both companies navigate evolving market dynamics in early 2026.
Full story: https://getfinancebrief.com/story/wall-street-zen-downgrades-alhc-frsh-hold

### Wall Street Zen Issues Multi-Sector Downgrades for FEED, CLBT, and MVIS
2026-03-10 08:02:13 · Sentiment: Neutral · Impact: 5/10 · Sources: 4

Wall Street Zen has issued a series of ratings downgrades targeting a diverse group of companies including NanoVibronix, Cellebrite, MicroVision, and The Honest Company. These moves signal a shift in sentiment toward high-growth and speculative tech sectors as analysts re-evaluate valuation and performance metrics.
Full story: https://getfinancebrief.com/story/wall-street-zen-downgrades-feed-clbt-mvis-hnst

### Wall Street Zen Adjusts Outlook on Tapestry and Sysco Amid Market Shifts
2026-03-10 06:30:16 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wall Street Zen has lowered its ratings for luxury fashion house Tapestry and foodservice giant Sysco, signaling a more cautious stance on these sector leaders. The adjustments reflect shifting valuation dynamics and macroeconomic headwinds facing the consumer discretionary and staples sectors.
Full story: https://getfinancebrief.com/story/tapestry-sysco-rating-downgrades-wall-street-zen

### Wall Street Zen Issues Bullish Upgrades for WFRD, DCBO, and ORGO
2026-03-08 08:30:40 · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Analyst firm Wall Street Zen has issued significant rating upgrades for Weatherford International, Docebo, and Organogenesis. These shifts to 'Buy' and 'Strong-Buy' status signal a positive fundamental outlook across the energy, enterprise software, and healthcare sectors.
Full story: https://getfinancebrief.com/story/wall-street-zen-upgrades-wfrd-dcbo-orgo

### Wall Street Zen Downgrades Plexus and Life360 to Hold Amid Growth Revaluation
2026-03-08 08:27:14 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wall Street Zen has downgraded both electronic manufacturing services provider Plexus (PLXS) and family safety platform Life360 (LIF) to Hold ratings. These shifts reflect a cautious stance on mid-cap growth and industrial tech as investors weigh valuation against near-term execution risks.
Full story: https://getfinancebrief.com/story/plexus-life360-downgraded-wall-street-zen

### Momentum Plays: Edgewise and Ericsson Hit 52-Week Highs Amid Sector Shifts
2026-02-27 17:05:29 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Edgewise Therapeutics and Ericsson have both breached 52-week price peaks, signaling robust investor confidence in biotech innovation and telecom infrastructure recovery. While Edgewise benefits from clinical momentum in muscle disease treatments, Ericsson's ascent reflects a stabilized global 5G landscape and a strategic pivot toward AI-native networking.
Full story: https://getfinancebrief.com/story/edgewise-ericsson-52-week-highs-analysis

### Wall Street Zen Issues Triple Buy Upgrades for Medtronic, Reliance, and ESI
2026-02-22 10:31:08 · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Wall Street Zen has upgraded Medtronic, Reliance, and Element Solutions to 'Buy' ratings, signaling a bullish outlook across healthcare and industrial sectors. These upgrades reflect a strategic pivot toward high-quality dividend payers and market leaders as industrial demand stabilizes.
Full story: https://getfinancebrief.com/story/wall-street-zen-upgrades-mdt-rs-esi

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.